BDTX-1535, actually in a phase I/II dose expansion study, has demonstrated to be active in NSCLC patients across nearly all EGFR mutations, including T790M, C797S, L747P, L718Q, and compound mutations [52]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.